Ardigen has proudly joined the ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium as a tech partner and collaborator. This partnership positions Ardigen alongside prominent industry leaders (such as Amazon Web Services, Axiom Bio, BioSpyder, EU-OPENSCREEN, Nomic Bio, Revvity, and Xellar Biosystems) along with many government and academic organizations in a collaborative effort to push the boundaries of multi-omics technologies for safety assessment.
Ardigen’s role as a tech partner involves contributing our expertise in data analysis, including our extensive experience and cutting-edge approaches to analyzing Cell Painting data. Ardigen will contribute to all consortium activities and the broader HESI Emerging Systems Toxicology for the Assessment of Risk (eSTAR) initiative. Additionally, Ardigen and other industry partners have the opportunity to add compounds of interest to the studies, enhancing the collaborative potential of the research.
The OASIS Consortium is tackling some of the biggest challenges in toxicology and drug development. Ardigen’s partnership with OASIS emphasizes its commitment to harnessing data-driven technologies for advancing drug discovery and development research and insights into human health. Together with its partners, Ardigen looks forward to contributing to the development of next-generation safety assessment methods and furthering innovation in toxicology.
